Shanghai Pharmaceuticals Holding Co Ltd banner

Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607

Watchlist Manager
Shanghai Pharmaceuticals Holding Co Ltd Logo
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Watchlist
Price: 17.31 CNY 0.52% Market Closed
Market Cap: ¥64.2B

Shanghai Pharmaceuticals Holding Co Ltd
Total Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Shanghai Pharmaceuticals Holding Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Total Current Liabilities
¥139B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
14%
Sinopharm Group Co Ltd
HKEX:1099
Total Current Liabilities
¥279.9B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
11%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Total Current Liabilities
¥74.6B
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
14%
C
China National Medicines Corp Ltd
SSE:600511
Total Current Liabilities
¥14.2B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
18%
Huadong Medicine Co Ltd
SZSE:000963
Total Current Liabilities
¥14.6B
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
8%
C
China National Accord Medicines Corp Ltd
SZSE:000028
Total Current Liabilities
¥27.5B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
12%
No Stocks Found

Shanghai Pharmaceuticals Holding Co Ltd
Glance View

Market Cap
64.2B CNY
Industry
Health Care

Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.

Shanghai Pharmaceuticals Holding Co Ltd Intrinsic Value
HIDDEN
Show

See Also

What is Shanghai Pharmaceuticals Holding Co Ltd's Total Current Liabilities?
Total Current Liabilities
139B CNY

Based on the financial report for Sep 30, 2025, Shanghai Pharmaceuticals Holding Co Ltd's Total Current Liabilities amounts to 139B CNY.

What is Shanghai Pharmaceuticals Holding Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
14%

Over the last year, the Total Current Liabilities growth was 7%. The average annual Total Current Liabilities growth rates for Shanghai Pharmaceuticals Holding Co Ltd have been 9% over the past three years , 11% over the past five years , and 14% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett